BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Watson Pharmaceuticals, Inc. (WPI) Receives FTC Clearance For Andrx Corporation (ADRX) Acquisition


11/1/2006 10:17:44 AM

CORONA, Calif. and FT. LAUDERDALE, Fla., Oct. 31 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission ("FTC") has accepted a proposed consent order for public comment relating to Watson's pending acquisition of Andrx Corporation , and granted early termination of the Hart Scott Rodino waiting period, thereby permitting the parties to close the transaction. The parties have now obtained all regulatory approvals required to close the transaction. Accordingly, the parties expect to consummate the acquisition of Andrx by Watson on November 3, 2006.

Under the terms of a consent order with the FTC, Watson and Andrx have agreed to the following conditions to complete the acquisition:

* Watson will terminate its agreement with Interpharm, Inc. related to the distribution of Interpharm's hydrocodone ibuprofen 7.5mg/200mg product. Interpharm will initiate direct sales of the product upon the close of the transaction. * Andrx will sell to Actavis Group hf its pending Abbreviated New Drug Applications (ANDAs) for glipizide extended-release, 2.5, 5 and 10mg, and will assign to Actavis its rights under an existing supply agreement with Pfizer, pursuant to which Andrx currently distributes glipizide extended-release tablets manufactured by Pfizer. * Teva Pharmaceuticals USA will acquire all of Andrx's ownership interests in its portfolio of oral contraceptive products. Teva currently holds exclusive marketing rights to such products.

Watson does not consider the marketed products to be divested pursuant to the consent order to be material to Watson.

About Watson

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

About Andrx Corporation Andrx is a pharmaceutical company that: * develops and commercializes generic versions of primarily controlled-release pharmaceutical products as well as oral contraceptives, and selective immediate-release products; * distributes pharmaceutical products, primarily generics, which have been commercialized by others, as well as our own, primarily to independent and chain pharmacies and physicians' offices; and * develops and manufactures pharmaceutical products for other pharmaceutical companies, including combination products and controlled-release formulations. Cautionary Language Concerning Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Securities Litigation Reform Act. All statements included in this press release that address activities, events or developments that Watson and Andrx expect, believe or anticipate will or may occur in the future are forward-looking statements, including the expected timing of the merger of the two companies and the expected divestment of certain product lines. These statements are based on certain assumptions made by Watson and Andrx based on their experience and perception of historical trends, current conditions, expected future developments and other factors they believe are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Watson and Andrx. Any such projections or statements include the current views of Watson and Andrx with respect to future events and financial performance. No assurances can be given, however, that these events will occur or that such results will be achieved. There are a number of important factors that could cause actual results to differ materially from those projected, including the risks of pending or future litigation or government investigations; and other risks described from time to time in Watson's and Andrx's Securities and Exchange Commission ("SEC") filings including Watson's and Andrx's Annual Report on Form 10-K for the year ended December 31, 2005 and Form 10-Q for the period ended June 30, 2006. Watson and Andrx disclaim any intent or obligation to update any forward-looking statements contained herein, which speak as of the date hereof.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.

CONTACT: Patty Eisenhaur of Watson Pharmaceuticals, Inc., +1-951-493-5611



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->